Pacific Center for Emerging Infectious Diseases Research
太平洋新发传染病研究中心
基本信息
- 批准号:9098820
- 负责人:
- 金额:$ 115.5万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-07-01 至 2020-06-30
- 项目状态:已结题
- 来源:
- 关键词:AccountingAffectAnimalsAreaAsiaAvian InfluenzaAwardBasic ScienceBioinformaticsBiological SciencesBiomedical ResearchBusinessesCellular ImmunologyCenter for Translational Science ActivitiesCenters of Research ExcellenceChinaClinical ResearchCollaborationsCommunicable DiseasesCommunitiesDataDevelopmentDiagnosticDiagnostic testsEbola virusEconomicsEmerging Communicable DiseasesEnsureEpidemicEpigenetic ProcessExtramural ActivitiesFacultyFosteringFoundationsFundingFuture GenerationsGeneticGoalsGrantGrowthGuineaHawaiiHawaiian populationHealthHealth Services ResearchHumanInfectious Diseases ResearchInstitutionInternationalInvestmentsLiberiaMentorsMicrobiologyMiddle East Respiratory Syndrome CoronavirusMissionModelingMolecular ImmunologyMonitorMovementNational Institute of General Medical SciencesNutritionalPacific Island AmericansPakistanParasitesPhasePoliomyelitisPopulation GrowthPositioning AttributePreventionPreventive MedicinePrincipal InvestigatorProductivityPublic HealthRecruitment ActivityResearchResearch InfrastructureResearch PersonnelResearch PriorityResource SharingResourcesScienceScientistSierra LeoneSpeedStreamSystemTherapeuticTrainingTraining SupportTraining and EducationTranslational ResearchTriad Acrylic ResinTropical MedicineUnited States National Institutes of HealthUniversitiesUrbanizationVaccinesbasebiobehaviordisease diagnosisethnic disadvantageethnic minority populationgraduate studenthigher educationimprovedmicrobialnext generationnovel vaccinesoperationprogramspublic health relevanceresearch and developmentsocial
项目摘要
DESCRIPTION (provided by applicant): Established in 2003, the Pacific Center for Emerging Infectious Diseases Research, a translational science center of excellence supported by funding from the Centers of Biomedical Research Excellence (COBRE) component of the Institutional Development Award (IDeA) program, seeks to develop and deploy rapid diagnostics, improved therapeutics and affordable vaccines for new, emerging and re-emerging infectious diseases that disproportionately affect underserved communities in the Asia-Pacific region. The COBRE Center also seeks to increase the diversity of the biomedical research workforce by training and mentoring native Hawaiians and other underrepresented Pacific Islanders. Thus, the Center's mission is thoroughly consistent with that of the National Institute of General Medical Sciences, which is to support basic research that lays the foundation for advances in disease diagnosis, treatment and prevention, and to increase the diversity of the research workforce by supporting the training of the next generation of scientists (http://www.nigms.nih.gov/About/Pages/default.aspx). The principal objective of the Phase III COBRE for emerging infectious diseases is to enhance the conditions that accelerate the pace of scientific discovery, heighten research productivity and increase competitiveness for extramural funding. The objective will be achieved by (1) enhancing the growth and sustainability of the COBRE cores in biocontainment, bioinformatics, and molecular and cellular immunology, which are grounded in the triad of customized and collaborative service, research and development, and education and training; and (2) developing and implementing a COBRE Small Grants Program, without borders, that fosters collaborations and partnerships, promotes data and resource sharing, and provides additional opportunities for mentoring and specialized training across IDeA-funded centers in research aimed at improving human health. COBRE funding during Phases I and II has transformed the landscape for mentoring and training future generations of investigators and has provided state-of-the-art core resources for multi-disciplinary collaborative research on epidemic infectious diseases. At the institutional level, COBRE funding has spurred significant commitments to recruit and retain a new cadre of productive faculty, and such efforts will continue into Phase III. High-level upper-administrative institutional commitments will ensure the sustainability of the Center and its cores beyond the Phase III COBRE period.
描述(由申请人提供):太平洋新发传染病研究中心成立于 2003 年,是一个卓越的转化科学中心,由机构发展奖 (IDeA) 计划的生物医学研究卓越中心 (COBRE) 的资金支持,致力于针对新出现和重新出现的传染病开发和部署快速诊断、改进的治疗方法和负担得起的疫苗,这些疾病对亚太地区服务不足的社区造成了不成比例的影响。 COBRE 中心还寻求通过培训和指导夏威夷土著和其他代表性不足的太平洋岛民来增加生物医学研究队伍的多样性,因此,该中心的使命与国家普通医学科学研究所的使命完全一致,即支持基础医学。研究为疾病诊断、治疗和预防的进步奠定基础,并通过支持下一代科学家的培训来增加研究队伍的多样性(http://www.nigms.nih.gov/About/Pages/default.aspx) 针对新发传染病的第三阶段 COBRE 的主要目标是改善加快科学发现步伐、提高研究生产力的条件。该目标将通过以下方式实现:(1) 加强生物防护、生物信息学以及分子和细胞免疫学方面的 COBRE 核心的增长和可持续性,这些核心以以下三方面为基础:定制和协作服务、研究与开发以及教育和培训;(2) 制定和实施无国界的 COBRE 小额赠款计划,以促进合作和伙伴关系,促进数据和资源共享,并提供额外的指导和专业机会在第一阶段和第二阶段,IDeA 资助的研究中心开展了旨在改善人类健康的培训,这改变了指导和培训下一代研究人员的格局,并为多学科合作提供了最先进的核心资源。传染病研究在机构层面,COBRE 的资助促使人们做出了重大承诺,招募和留住新的富有成效的教师队伍,这种努力将持续到第三阶段,高层管理机构的承诺将确保该中心及其中心的可持续性。超过第三阶段 COBRE 时期的核心。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
RICHARD YANAGIHARA其他文献
RICHARD YANAGIHARA的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('RICHARD YANAGIHARA', 18)}}的其他基金
Puipuia le Ola: Increasing reach and uptake of COVID-19 testing among Pacific Islanders in Hawaii and Guam
Puipuia le Ola:在夏威夷和关岛的太平洋岛民中扩大 COVID-19 检测的覆盖范围和接受度
- 批准号:
10259631 - 财政年份:2020
- 资助金额:
$ 115.5万 - 项目类别:
Pacific Center for Emerging Infectious Diseases Research
太平洋新发传染病研究中心
- 批准号:
8883300 - 财政年份:2015
- 资助金额:
$ 115.5万 - 项目类别:
U HAWAII COBRE: ADMINISTRATIVE & MENTORING CORE
夏威夷大学 COBRE:行政
- 批准号:
8168406 - 财政年份:2010
- 资助金额:
$ 115.5万 - 项目类别:
Intraspecies Transmission and Infectivity of Insectivore-Borne Hantaviruses
食虫动物传播的汉坦病毒的种内传播和感染性
- 批准号:
8121416 - 财政年份:2008
- 资助金额:
$ 115.5万 - 项目类别:
Intraspecies Transmission and Infectivity of Insectivore-Borne Hantaviruses
食虫动物传播的汉坦病毒的种内传播和感染性
- 批准号:
7465229 - 财政年份:2008
- 资助金额:
$ 115.5万 - 项目类别:
Intraspecies Transmission and Infectivity of Insectivore-Borne Hantaviruses
食虫动物传播的汉坦病毒的种内传播和感染性
- 批准号:
7903204 - 财政年份:2008
- 资助金额:
$ 115.5万 - 项目类别:
Intraspecies Transmission and Infectivity of Insectivore-Borne Hantaviruses
食虫动物传播的汉坦病毒的种内传播和感染性
- 批准号:
7668615 - 财政年份:2008
- 资助金额:
$ 115.5万 - 项目类别:
相似国自然基金
城市化对土壤动物宿主-寄生虫关系的影响机制研究
- 批准号:32301430
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
三江源国家公园黄河源园区食草野生动物与放牧家畜冲突的强度、影响及未来情景
- 批准号:42371283
- 批准年份:2023
- 资助金额:46 万元
- 项目类别:面上项目
十年禁渔对赤水河底栖动物群落多样性及其维持机制的影响
- 批准号:32301370
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
两栖动物(蛙类)对新型卤代有机污染物的生物富集及其对污染物环境迁移影响的研究
- 批准号:42307349
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
土壤动物对草地生态系统地下食物网碳氮传输过程及土壤有机质形成的影响
- 批准号:32301359
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
SORDINO-fMRI for mouse brain applications
用于小鼠大脑应用的 SORDINO-fMRI
- 批准号:
10737308 - 财政年份:2023
- 资助金额:
$ 115.5万 - 项目类别:
An immunotherapeutic IgY formulation against norovirus diarrhea
一种针对诺如病毒腹泻的免疫治疗 IgY 制剂
- 批准号:
10693530 - 财政年份:2023
- 资助金额:
$ 115.5万 - 项目类别:
Impact of ambient PM2.5 concentrations on fear extinction recall, frontolimbic circuitry, and anxiety in adolescents
环境 PM2.5 浓度对青少年恐惧消退回忆、额边缘回路和焦虑的影响
- 批准号:
10749203 - 财政年份:2023
- 资助金额:
$ 115.5万 - 项目类别:
Determine the role of atmospheric particulate matter pollutants in contributing to Lewy Body Dementia
确定大气颗粒物污染物在路易体痴呆症中的作用
- 批准号:
10662930 - 财政年份:2023
- 资助金额:
$ 115.5万 - 项目类别:
Subchondral Trabecular Plate and Rod Abnormalities in Human Osteoarthritis
人类骨关节炎的软骨下小梁板和杆异常
- 批准号:
10660605 - 财政年份:2023
- 资助金额:
$ 115.5万 - 项目类别: